Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemis: ctDNA-Guided Boost Therapy in TNBC
NCT04803539Phase 3Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Apr 2021
- Primary completion
- Sep 2028
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab, Rivoceranib in triple-negative breast cancer (TNBC), sponsored by Sun Yat-sen Memorial Hospital. Started Apr 2021; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04803539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04803539.